The Peptide NewsroomPeptide research, industry and supply-chain headlines

Berkeley Compound Burned Fat Without Muscle Loss in Mice, But Human Testing Has Not Started

Topic card: glp-1

Researchers at the University of California, Berkeley have identified a compound that increased the amount of energy the body uses rather than simply reducing how much food is eaten, according to findings published in Science Advances. The compound, 5-tetradecyloxy-2-furoic acid or TOFA, was first discovered in the 1970s.

Everything reported here was done in mice, and the researchers say TOFA's effectiveness and safety have not yet been established in humans. That caveat matters more than usual in this story, because the appeal of the result is precisely the thing that is hardest to carry across species.

Why muscle loss is the opening

GLP-1 drugs sold as Ozempic, Wegovy, Mounjaro and Zepbound work almost entirely by cutting appetite and food intake, which the researchers note can raise the risk of inadequate nutrition and loss of muscle mass. Over time, losing too much muscle can contribute to weakness and frailty, and that is the gap the Berkeley team went after.

"Body weight responds to two levers: taking in fewer calories, or spending more energy," said Anders Naar, professor of metabolic biology and nutrition at Berkeley and senior author. "GLP-1s work almost entirely on the first, so we went after the second."

Key results

In obese mice, treatment increased energy expenditure by as much as 18%, without the animals becoming more physically active or running a higher body temperature. Weight came off primarily as body fat, with no significant loss of lean muscle mass, alongside improved insulin sensitivity, lower triglycerides and improved characteristics of fatty liver disease.

TOFA belongs to a class called ACC inhibitors, several of which have reached mid-stage trials without approval, often because they raised blood triglycerides. This one did not, which the team attributes to its additional activation of the PPAR-alpha and PPAR-delta receptors.

Limitations

All findings come from animal studies, and scientists have not established whether the compound is safe or effective in people. Whether the same metabolic improvements appear in humans, and whether they would offer any real advantage over existing medications, remains untested.

A combination, not a replacement

Paired with semaglutide or tirzepatide in mice, TOFA produced better results on weight, glucose, insulin and triglycerides than either treatment alone. The team has founded a company, ReRx Therapeutics, to push the work forward, and frames the compound as complementary rather than a substitute.

Source: ScienceDaily — Pharmacology. Read the original.

Filed under: glp-1, muscle

Comments (0)

Discussion happens on Reddit.
Questions and corrections go to r/PeptideNewsroom.

Go to r/PeptideNewsroom

Corrections are the most useful thing you can post. Comments touching dosing, sourcing or links are held for a moderator first.

More from The Peptide Newsroom

What the Research Actually Says About Semaglutide, From Weight Loss to Memory

Semaglutide has large human trials behind its weight and metabolic outcomes, but the newer questions about energy expenditure, muscle preservation and cognition are far less settled. A digest of what researchers have actually reported, and where the evidence stops.

Kemin Pitches Positive Aging, GLP-1 Support and Gut Health as Its 2027 Trends

Kemin's Filipa Quintela told Nutritional Outlook at SupplySide Global that positive aging, GLP-1 support through Slendesta, and gut health via the Gutopia platform will shape the supplier's 2027 development. She also put American lutein intake at around 2 mg a day against an optimal 10 mg.

Ingredient Supplier Kemin Puts GLP-1 Companion Nutrition at the Center of Its 2027 Outlook

At SupplySide Global, ingredient developer Kemin outlined a 2027 wellness outlook built on GLP-1 companion nutrition, gut health, and positive aging, with FloraGLO Lutein repositioned toward cognition. No trial data or outcome figures appear anywhere in the coverage, which makes this a supplier forecast rather than new evidence.